- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01500954
Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma
October 15, 2012 updated by: Michael Sand, Ruhr University of Bochum
MicroRNAs (miRNAs) are a novel class of short RNAs which have shown to be dysregulated in a variety of cancers.
Data of miRNA expression in cutaneous squamous cell carcinoma (cSCC) is very limited and microarray based genome wide miRNA expression profiles of cSCC have not been investigated so far.
Study Overview
Status
Completed
Conditions
Detailed Description
Patients with cutaneous SCC were enrolled in the present study.
Tumor biopsies were taken from the center of the tumor.
Adjacent healthy skin was biopsied as a control (intraindividual control).
miRNA expression profiles of specimen were detected by microarray miRNA expression profiling.
Microarray results were confirmed by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).
Study Type
Observational
Enrollment (Actual)
7
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
NRW
-
Bochum, NRW, Germany, 44791
- Department of Dermatology, Venereology and Allergology, Dermatologic Surgery Unit, Ruhr-University Bochum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with cutaneous squamous cell carcinoma
Description
Inclusion Criteria:
- cutaneous squamous cell carcinoma
Exclusion Criteria:
- other skin cancer than cutaneous squamous cell carcinoma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
squamous cell carcinoma
|
non-lesional skin
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Falk G Bechara, PD Dr., Department of Dermatology, Venereology and Allergology, Dermatologic Surgery Unit, Ruhr-University Bochum
- Study Chair: Peter Altmeyer, Prof. Dr., Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
- Principal Investigator: Michael Sand, Dr., Department of Dermatology, Venereology and Allergology, Dermatologic Surgery Unit, Ruhr-University Bochum
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Actual)
December 1, 2011
Study Completion (Actual)
December 1, 2011
Study Registration Dates
First Submitted
December 23, 2011
First Submitted That Met QC Criteria
December 28, 2011
First Posted (Estimate)
December 29, 2011
Study Record Updates
Last Update Posted (Estimate)
October 16, 2012
Last Update Submitted That Met QC Criteria
October 15, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- microRNA7
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Squamous Cell Carcinoma
-
Replimune Inc.Regeneron PharmaceuticalsActive, not recruitingCutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell CarcinomaSpain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
Regeneron PharmaceuticalsNot yet recruiting
-
The Netherlands Cancer InstituteRecruitingCutaneous Squamous Cell CarcinomaNetherlands
-
Queen Mary University of LondonActive, not recruiting
-
Fondazione Melanoma OnlusActive, not recruitingCutaneous Squamous Cell CarcinomaItaly
-
H. Lee Moffitt Cancer Center and Research InstituteWithdrawnCutaneous Squamous Cell CarcinomaUnited States
-
Melanoma Institute AustraliaBristol-Myers SquibbNot yet recruitingCutaneous Squamous Cell Carcinoma
-
Shanghai Henlius BiotechRecruitingCutaneous Squamous Cell CarcinomaChina
-
Stanford UniversityGenentech, Inc.Active, not recruitingCutaneous Squamous Cell CarcinomaUnited States